At 1.32 billion people, India may have, according to recent reports, already overtaken China’s population. Contrast this: a group of Israeli investors plan to pump $10 million (Rs 65 crore) into an Indian in-vitro fertilisation (IVF) company’s expansion into tier-II and III cities to treat infertility and bless childless couples with affordable parenthood.

“We are in an advanced stage of talks for this funding. By September, we expect to clinch the deal,” Dr Sahil Gupta, the 29-year-old entrepreneur who founded Aveya Fertility & IVF Centre in New Delhi, told BusinessLine .

Since its inception in 2015, Aveya has been providing high-quality, cost-effective care to an average 60 couples per month, he said.

Aveya’s USP, he said, was based on the IVF model preferred in Japan and Europe, where intake of medicines is minimised to encourage healthy pregnancy and parenthood. Aveya offers natural cycle IVF, without much medication or side-effects. “Many countries are now following zero-medication IVF models.”

“Unlike other Indian IVF service providers, who charge anywhere between Rs 1.5 to Rs 2 lakh, we run a low-cost service at a minimum of Rs 35,000 only. However, we also provide premium services ranging up to Rs 2 lakh per case,” Dr Gupta said.

Currently based in New Delhi, Aveya plans to expand in a phased manner to 10 Tier-II and III cities in India in the next two years.

Besides, Dr Gupta said, Aveya is also looking at an overseas market, starting with Kathmandu (Nepal) in the next two years.

Aveya boasts of a team of international healthcare experts from the US, Israel, Germany, Spain and Japan, and takes care of the beneficiaries’ emotional and spiritual requirements as well.

Its turnover is expected to be around $2 million (Rs 13 crore) this year. Among the services it provides are surrogacy, egg freezing, egg donation and refunds.